# TABLE OF CONTENTS

## CHAPTER 1

**INTRODUCTION**

1.1 Drugs  
1.2 Cardiovascular drugs  
1.3 Impurity profiling  
1.4 Analytical methods  
References  

## CHAPTER 2

**SCOPE OF THE RESEARCH**

2.0 Scope of the Research  

## CHAPTER 3

**IDENTIFICATION AND CHARACTERIZATION OF A PRINCIPAL OXIDATION IMPURITY IN CLOPIDOGREL DRUG SUBSTANCE AND DRUG PRODUCT**

3.1 Introduction  
3.2 Drug profile  
3.3 Literature review  
3.4 Scope of the study  
3.5 Experimental  
3.6 Results and discussion  
3.7 Conclusion  
References  

## CHAPTER 4

**IDENTIFICATION, ISOLATION AND CHARACTERIZATION OF FIVE POTENTIAL DEGRADATION IMPURITIES IN CANDESARTAN CILEXETIL TABLETS**

4.1 Introduction  
4.2 Drug Profile  
4.3 Literature review  
4.4 Scope of the study  
4.5 Experimental  
4.6 Results and Discussion  
4.7 Formation of impurities  

References  

CHAPTER 5

DEVELOPMENT OF A VALIDATED REVERSED PHASE UPLC METHOD FOR RELATED SUBSTANCES AND ASSAY OF LACIDIPINE

5.1 Introduction
5.2 Drug profile
5.3 Literature review
5.4 Scope of the study
5.5 Experimental
5.6 Results and Discussion
5.7 Results of method validation experiments
5.8 Conclusion

References

CHAPTER 6

DEVELOPMENT AND VALIDATION OF A DISSOLUTION METHOD FOR NOVEL FIXED DOSE COMBINATION OF ETODOLAC AND PROPRANOLOL HYDROCHLORIDE TABLETS BY RP-HPLC

6.1 Introduction
6.2 Drug profile
6.3 Literature review
6.4 Scope of the study
6.5 Experimental
6.6 Method validation
6.7 Results and Discussion
6.8 Results of method validation experiments
6.9 Conclusion

References